H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC
29. Dezember 2022 07:00 ET | H-CYTE, Inc.
Wound Healing and Limb Salvage Technology Added to Growing Asset PortfolioCompany’s Second Completed Transaction in Four Months TAMPA, Fla., Dec. 29, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB:...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days
19. September 2022 07:00 ET | H-CYTE, Inc.
TAMPA, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company has entered into a letter of intent to acquire SkinDisc, a...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Completes Acquisition of Jantibody
08. September 2022 07:00 ET | H-CYTE, Inc.
TAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed the acquisition of Jantibody. Highlights: ...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
22. Juli 2022 07:00 ET | H-CYTE, Inc.
TAMPA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company expects to close its acquisition of Jantibody within the...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Announces 1-for-1,000 Reverse Stock Split
13. Juni 2022 07:00 ET | H-CYTE, Inc.
TAMPA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that the Board approved a 1-for-1,000 reverse stock split, effective 9:30...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
04. März 2022 09:18 ET | H-CYTE, Inc.
TAMPA, Fla., March 04, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that it has received $1,053,605 from the exercise of 75,257,511 previously...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
11. Januar 2022 08:00 ET | H-CYTE, Inc.
TAMPA, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that it has entered into a letter of intent for the acquisition of Catheter...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Names Michael Yurkowsky Chief Executive Officer
06. Dezember 2021 08:00 ET | H-CYTE, Inc.
TAMPA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced that it has named Michael...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health
08. September 2021 08:00 ET | H-CYTE, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic...
H-Cyte-Logo-Final-CMYK (1).jpg
H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health
06. Juli 2021 08:00 ET | H-CYTE, Inc.
TAMPA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of new data...